Alterity Therapeutics has secured FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy (MSA), a rare neurodegenerative disease. The FDA approved the study population, dosing regimen of 50 mg twice daily, and primary endpoint UMSARS Part I, following positive Phase 2 results showing 48% slowing of disease progression. The Phase 3 trial, involving about 200 patients, is set to start by the end of 2026 and aims to support a New Drug Application. This milestone reduces regulatory uncertainty and advances ATH434 as a potential disease-modifying therapy for MSA, which currently has no approved treatments.
Taiwan Semiconductor Manufacturing Company (TSMC) reported a 23.4% increase in second-quarter profit from the previous quarter, surpassing analyst estimates. The company's net income reached NT$706.56 billion ($39.45 billion), a record high for the f...
National Beverage faces stagnant growth as LaCroix volumes have declined for four straight years, reducing brand excitement. The stock trades at reasonable multiples reflecting muted growth and no clear catalysts for upside. Despite stable gross marg...
Arthur Hayes reversed his crypto strategy by purchasing over $3.7 million worth of Ethereum after selling 6,000 ETH at a loss of about $606,000 just weeks prior. This move follows his pattern of bold crypto trades and quick exits, which have drawn cr...
A bitcoin wallet that had been inactive since 2017 moved its entire holding of 5,908 BTC, now worth about $383 million, to a new, unidentified address. The coins were originally bought near bitcoin's 2017 peak at around $16,000 each and have gained r...
Zcash (ZEC) is approaching the $600 mark after breaking out of a multi-week consolidation, showing strong bullish momentum. The price has surpassed key moving averages and resistance levels, supported by healthy trading volume and positive technical ...
